Risk prediction of developing venous thrombosis in combined oral contraceptive users
Authors:
Open Access
- 27 July 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (7) , e0182041
Abstract
Venous thromboembolism (VTE) is a complex multifactorial disease influenced by genetic and environmental risk factors. An example for the latter is the regular use of combined oral contraceptives (CC), which increases the risk to develop VTE by 3 to 7 fold, depending on estrogen dosage and the type of progestin present in the pill. One out of 1'000 women using CC develops thrombosis, often with life-long consequences; a risk assessment is therefore necessary prior to such treatment. Currently known clinical risk factors associated with VTE development in general are routinely checked by medical doctors, however they are far from being sufficient for risk prediction, even when combined with genetic tests for Factor V Leiden and Factor II G20210A variants. Thus, clinical and notably genetic risk factors specific to the development of thrombosis associated with the use of CC in particular should be identified. Step-wise (logistic) model selection was applied to a population of 1622 women using CC, half of whom (794) had developed a thromboembolic event while using contraceptives. 46 polymorphisms and clinical parameters were tested in the model selection and a specific combination of 4 clinical risk factors and 9 polymorphisms were identified. Among the 9 polymorphisms, there are two novel genetic polymorphisms (rs1799853 and rs4379368) that had not been previously associated with the development of thromboembolic event. This new prediction model outperforms (AUC 0.71, 95% CI 0.69–0.74) previously published models for general thromboembolic events in a cross-validation setting. Further validation in independent populations should be envisaged. We identified two new genetic variants associated to VTE development, as well as a robust prediction model to assess the risk of thrombosis for women using combined oral contraceptives. This model outperforms current medical practice as well as previously published models and is the first model specific to CC use.Keywords
This publication has 24 references indexed in Scilit:
- Multiple SNP testing improves risk prediction of first venous thrombosisBlood, 2012
- KNG1 Ile581Thr and susceptibility to venous thrombosisBlood, 2011
- Genetic variants associated with deep vein thrombosis: the F11 locusJournal of Thrombosis and Haemostasis, 2009
- Genetics of venous thrombosisJournal of Thrombosis and Haemostasis, 2009
- The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndromeBMC Cardiovascular Disorders, 2008
- An introduction to ROC analysisPattern Recognition Letters, 2006
- Inherited Risk Factors for Venous ThrombosisHematology-American Society Hematology Education Program, 2005
- THE INVOLVEMENT OF CYP3A4 AND CYP2C9 IN THE METABOLISM OF 17α-ETHINYLESTRADIOLDrug Metabolism and Disposition, 2004
- A haplotype of the EPCR gene is associated with increased plasma levels of sEPCR and is a candidate risk factor for thrombosisBlood, 2004
- Genetic Susceptibility to Venous ThrombosisNew England Journal of Medicine, 2001